Sorafenib News and Research

RSS
Sorafenib (Nexavar) is an oral multikinase inhibitor for the treatment of two common types of cancer, hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC).
Repurposing drugs to outsmart cancers

Repurposing drugs to outsmart cancers

Platinum nanoparticles show selective toxicity against liver cancer cells

Platinum nanoparticles show selective toxicity against liver cancer cells

Physicians more likely to prescribe drugs of manufacturers who paid them money

Physicians more likely to prescribe drugs of manufacturers who paid them money

FOTIVDA expected to be included in new ESMO guidelines for advanced renal cell carcinoma

FOTIVDA expected to be included in new ESMO guidelines for advanced renal cell carcinoma

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

New nanoplatform technology may reverse drug-resistance in renal cell carcinoma

New nanoplatform technology may reverse drug-resistance in renal cell carcinoma

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

CHMP provides positive opinion to Cabometyx for previously-treated patients with hepatocellular carcinoma

CHMP provides positive opinion to Cabometyx for previously-treated patients with hepatocellular carcinoma

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

Eisai: EC approves marketing of LENVIMA as first-line treatment for hepatocellular carcinoma

Eisai: EC approves marketing of LENVIMA as first-line treatment for hepatocellular carcinoma

Scientists develop novel peptide drug that could potentially stop development of liver cancer

Scientists develop novel peptide drug that could potentially stop development of liver cancer

U.S. researchers recommend development of anti-cancer drugs based on mechanism of Namodenoson

U.S. researchers recommend development of anti-cancer drugs based on mechanism of Namodenoson

Can-Fite provides update on Phase II clinical trial with drug candidate Namodenoson

Can-Fite provides update on Phase II clinical trial with drug candidate Namodenoson

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Study confirms no survival benefit of adding SIRT to standard treatment for liver cancer

Study confirms no survival benefit of adding SIRT to standard treatment for liver cancer

Scientists find new way to kill liver cancer cells

Scientists find new way to kill liver cancer cells

New organ-on-a-chip technology provides simple setting to study blood vessel formation

New organ-on-a-chip technology provides simple setting to study blood vessel formation

Researchers use gold nanoshells to effectively release cancer drugs inside tumors

Researchers use gold nanoshells to effectively release cancer drugs inside tumors

Reduced dose of chemotherapy has no effect on overall survival of liver cancer patients

Reduced dose of chemotherapy has no effect on overall survival of liver cancer patients